Compare Ishares Msci Brazil ETF (EWZ) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $42.01 (market cap $13.14B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Ishares Msci Brazil ETF is the larger of the two by market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| EWZ | SYRE | |
|---|---|---|
Market Cap | $13.14B | $7.52B |
Volume | 52,443,793 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $108.92 |
52-Week Low | $29.24 | $22.18 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.87, down 1.54% today, with a bullish technical signal driven by moving averages but showing overbought RSI levels. The ETF is attracting significant attention due to Brazil's upcoming October election, with institutional investors accumulating positions through call options. Recent news highlights EWZ as a diversification tool against U.S. tech concentration and potential beneficiary of Brazilian economic policies.
The outlook for EWZ hinges on Brazil's political election outcome and commodity trends, offering asymmetric upside but facing currency and political volatility risks. Wall Street positioning suggests optimism, though investors must weigh the ETF's higher expense ratio against alternatives like FLBR for Brazilian exposure.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
